
    
      This study used a multi-center, randomized, blinded, double-dummy placebo controlled,
      three-period crossover design to assess the effect of once daily QVA149 q.d vs. placebo and
      tiotropium 18 Î¼g q.d. in terms of patient reported dyspnea as assessed by Baseline Dyspnea
      Index (BDI)/Transient Dyspnea Index (TDI)(SAC version) in patients with moderate to severe
      COPD.
    
  